Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes
D P Chew1, F A Anderson, A Avezum
1Department of Cardiovascular Medicine, Flinders University, Adelaide, South Australia, Australia. derek.chew@flinders.edu.au
Insights
Guideline-recommended therapies like percutaneous coronary intervention and coronary artery bypass graft surgery significantly improve survival for acute coronary syndrome (ACS) patients. Statins and clopidogrel also offer substantial pharmacologic benefits.
Area of Science:
- Cardiology
- Clinical Research
- Public Health
Background:
- Acute coronary syndrome (ACS) management involves multiple guideline-advocated therapies.
- Optimizing therapy selection is crucial for improving patient survival outcomes.
Purpose of the Study:
- To identify guideline-advocated therapies providing the greatest 6-month survival benefit in hospitalized ACS patients.
- To evaluate the comparative effectiveness of various ACS treatments.
Main Methods:
- A nested case-control study using the Global Registry of Acute Coronary Events (GRACE) cohort (1999-2007).
- Comparison of evidence-based medication use and coronary interventions (angiography, PCI, CABG) between survivors and non-survivors.
- Logistic regression analysis to calculate attributable mortality for incomplete therapy application.
Main Results:
- Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery showed the largest survival benefits (ORs 0.57 and 0.60, respectively).
- Statins and clopidogrel demonstrated the greatest independent pharmacologic benefits (ORs 0.85 and 0.84, respectively).
- Diminishing survival benefits were observed with each additional therapy administered.
Conclusions:
- PCI and CABG are associated with the most significant improvements in 6-month survival for ACS patients.
- Statins and clopidogrel offer key pharmacologic advantages in ACS management.
- These findings support evidence-based selection of ACS therapies, considering cost and compliance.
Aims:
The authors sought to define which guideline-advocated therapies are associated with the greatest benefit with respect to 6-month survival in patients hospitalised with an acute coronary syndrome (ACS).
Methods And Results:
The authors conducted a nested case-control study of ACS patients within the Global Registry of Acute Coronary Events cohort between April 1999 and December 2007. The cases were ACS patients who survived to discharge but died within 6 months. The controls were patients who survived to 6 months, matched for ACS diagnosis, age and the Global Registry of Acute Coronary Events risk score. Rates of use of evidence-based medications and coronary interventions (angiography, percutaneous coronary intervention and coronary artery bypass graft surgery) were compared. Logistic regression including matched variables was used, and the attributable mortality from incomplete application of each therapy was calculated. A total of 1716 cases and 3432 controls were identified. Coronary artery bypass graft surgery and percutaneous coronary intervention were associated with the greatest 6-month survival benefit (OR for death 0.60 (95% CI 0.39 to 0.90) and 0.57 (0.48 to 0.72), respectively). Statins and clopidogrel provided the greatest independent pharmacologic benefit (ORs for death 0.85 (0.73 to 0.99) and 0.84 (0.72 to 0.99)) with lesser effects seen with other pharmacotherapies.
Conclusions:
A diminishing benefit associated with each additional ACS therapy is evident. These data may provide a rational basis for selecting between therapeutic options when compliance or cost is an issue.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations